Diabetic foot infections: Microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus

International Wound Journal

Volumn 8, Issue 6, 2011, Pages 567-577

  Ambrosch, Andreas ^a   Haefner, Simone ^b   Jude, Edward ^c   Lobmann, Ralf ^b  

^a StJoseph Hospital Bremerhaven   (Germany)

^b Stuttgart General Hospital   (Germany)

^c TAMESIDE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Antibiotic therapy; Diabetic foot infection; MRSA

Indexed keywords

AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTAROLINE; CEFTAZIDIME; CEFTOBIPROLE; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FOSFOMYCIN; ICLAPRIM; LINEZOLID; LIPOPEPTIDE; ORITAVANCIN; RIFAMPICIN; TEFIBAZUMAB; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANAPHYLAXIS; ANTIBIOTIC THERAPY; ARTHRALGIA; BONE INFECTION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; DIABETIC FOOT; DIARRHEA; DRUG FEVER; DRUG INDUCED HEADACHE; ERYTHEMA; GASTROINTESTINAL SYMPTOM; GLOSSITIS; HEALTH CARE COST; HUMAN; INJECTION SITE PAIN; INSOMNIA; LACTIC ACIDOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OPTIC NERVE DISEASE; OTOTOXICITY; PATHOGENICITY; PERIPHERAL NEUROPATHY; PHLEBITIS; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RISK FACTOR; SKIN STRUCTURE; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOPHLEBITIS;

ANTI-BACTERIAL AGENTS; DIABETIC FOOT; HUMANS; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; WOUND INFECTION;

EID: 81155133827     PISSN: 17424801     EISSN: 1742481X     Source Type: Journal    
DOI: 10.1111/j.1742-481X.2011.00849.x     Document Type: Review

References (94)

1. Boulten AJ. The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes Metab Res Rev 2008;24 Suppl 1:S3-6.
2. New JP, McDowell D, Burns E, Young RJ. Problem of amputations in patients with newly diagnosed diabetes mellitus. Diabet Med 1998;15:760-4.
3. McGill M, Collins P, Bolton T, Yue DK. Management of neuropathic ulceration. J Wound Care 1996;5:52-4.
4. Apelquist J, Larsson J, Agardh CD. Long-term prognosis for diabetic patients with foot ulcers. J Intern Med 1993;233:485-91.
5. Williams DR. Hospital admissions of diabetic patients. Information from hospital activity analysis. Diabet Med 1985;2:27-32.
6. Armstrong DG, Lavery LA, Quebedeaux TL, Walker SC. Surgical morbidity and the risk of amputation due to infected puncture wounds in diabetics versus nondiabetic adults. J Am Podiatr Med Assoc 1997;87:321-6.
7. Boyko EJ, Ahroni JH, Smith DG, Davignon D. Increased mortality associated with diabetic foot ulcer. Diabet Med 1996;11:967-72.
8. DeFronzo RA, Reasner C. The diabetes control and complications trial study. Implications for the diabetic foot. J Foot Ankle Surg 1994;33:551-6.
9. Liebl A, Neiss A, Spannheimer A, Reitberger U, Wagner T, Gortz A. Costs of type 2 diabetes in Germany. Results of the CODE-2 study. Dtsch Med Wochenschr 2001;126:585-9.
10. Prompers L, Huijberts M, Schaper N, Apelqvist J, Bakker K, Edmonds M, Holstein P, Jude E, Jirkovska A, Mauricio D, Piaggesi A, Reike H, Spraul M, Van Acker K, Van Baal S, Van Merode F, Uccioli L, Urbancic V, Ragnarson Tennvall G. Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study. Diabetologia 2008;5:1826-34.
11. Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW. Assessment and management of foot disease in patients with diabetes. N Engl J Med 1994;331:854-60.
12. Mueller MJ. Therapeutic footwear helps protect the diabetic foot. J Am Podiatr Med Assoc 1997;87:360-4.
13. Spraul M. Internationaler konsensus über den diabetischen fuss. Mainz: Kirchheim, 1999.
14. Boyko EJ, Lipsky BA. Infection and diabetes mellitus. In: Harris MI, editor. Diabetes in America. NIH Publications No 95-1468. Bethesda: National Institutes of Health, 1995:485-99.
15. Pozzilli P, Leslie RDG. Infections and diabetes. Mechanisms and prospects of prevention. Diabet Med 1995;11:935-41.
16. Marhoffer W, Stein M, Maeser E, Federlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care 1992;15:256-60.
17. Balasubrmanyam M, Premanand C, Mohan V. The lymphocyte as a cellular model to study insights into the pathophysiology of diabetes and its complications. Ann N Y Acad Sci 2002;958:399-402.
18. Orie NN, Zidek W, Tepel M. Reactive oxygen species in essential hypertension and non-insulin-dependent diabetes mellitus. Am J Hypertens 1999;12:1169-74.
19. Moutschen MP, Scheen AJ, Lefebre PJ. Impaired immune responses in diabetes mellitus. Analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabetes Metab 1992;18:187-201.
20. Bouter KP, Meyling FH, Hoekstra JB, Masurel N, Erkelens DW, Diepersloot RJ. Influence of blood glucose levels on peripheral lymphocytes in patients with diabetes mellitus. Diabetes Res 1992;19:77-80.
21. Ludwicka A, Jansen B, Wadstroem T, Pulverer G. Attachment of staphylococci to various synthetic polymers. Zentralbl Bakteriol Hyg 1984;256:479-89.
22. Patti JM, Boles JO, Höök M. Identification and biochemical characterization of the ligand binding domain of collagen adhesin of Staphylococcus aureus. Biochemistry 1993;32:11428-35.
23. Greene C, Vaudaux PE, Francois P, Proctor RA, McDevitt D, Foster TJ. A low-fibronectin-binding mutant of Staphylococcus aureus 879R4S has Tn918 inserted into its single fnb gene. Microbiology 1996;142:2153-60.
24. Podbielska A, Galbowska H, Stelmach E, Mlynarczyk G, Olszewski WL. Slime production by Staphylococcus aureus and Staphylococcus epidermidis strains isolated from patients with diabetic foot ulcers. Arch Immunol Ther Exp 2010;58:321-4.
25. Bergamini TM, Corpus RA, Hoeg KL, Brittian KR, Peyton JC, Cheadle WG. Immune regulation of bacterial biofilm graft infection. ASAIO J 1994;40:219-26.
26. Steinberg D, Poran S, Shapira L. The effect of extracellular polysaccharides from Streptococcus mutans on the bactericidal activity of human neutrophils. Arch Oral Biol 1999;44:437-44.
27. Yasuda H, Ajiki Y, Aoyama J, Yokota T. Interaction between human polymorphonuclear leucocytes and bacteria released from in-vitro bacterial biofilm models. J Med Microbiol 1994;41:359-67.
28. Bjarnsholt T, Kirketerp-Moller K, Jensen PO, Madsen KG, Philipps R, Krogfelt K, Hoiby N, Givskov M. Why chronic wounds will not heal: a novel hypothesis. Wound Repair Regen 2008;16:2-10.
29. Roggenkamp A, Sing A, Hornef M, Brunner U, Autenrieth IB, Heesemann J. Chronic prosthetic hip infection caused by a small-colony variant of Escherichia coli. J Clin Microbiol 1998;36:2530-4.
30. Eiff C, von Heilmann C, Proctor RA, Woltz C, Peters G, Gotz F. A site-directed Staphylococcus aureus hemB mutant is a small-colony variant which persists intracellularly. J Bacteriol 1997;179:4706-12.
31. Eiff C, von Proctor RA, Peters G. Staphylococcus aureus small colony variants. Formation and clinical impact. Int J Clin Pract 2000;115:44-9.
32. Eiff C, von Lindner N, Proctor RA, Winkelmann W, Peters G. Development of gentamicin-resistant small colony variants of S. aureus after implantation of gentamicin chains in osteomyelitis as a possible cause of recurrence. Z Orthop Ihre Grenzgeb 1998;136:268-71.
33. Proctor RA, Peters G. Small colony variants in staphylococcal infections. Diagnostic and therapeutic implications. Clin Infect Dis 1998;27:419-22.
34. Sotto A, Gerard L, Richard JL, Combescure C, Bourg G, Vidal L, Jourdan N, Jerome E, Lavigne JP. Virulence potential of Staphylococcus aureus strains isolated from diabetic foot ulcers. Diabetes Care 2008;31:2318-24.
35. Meghji S, Crean SJ, Hill PA, Sheikh M, Nair SP, Heron K, Henderson B, Mawer EB, Harris M. Surface associated protein from Staphylococcus aureus stimulates osteoclasteogenesis. Possible role in S. aureus-induced bone pathology. Br J Rheumatol 1998;37:1095-101.
36. Lipsky BA, Tabak YP, Johannes RS, Vo L, Hyde L, Weigelt JA. Skin and soft tissue infections in hospitalized patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost. Diabetologia 2010;53:914-23.
37. Candel Gonzales FJ, Alramadan M, Matesanz M, Diaz A, González-Romo F, Candel I, Calle A, Picazo JJ. Infections in diabetic foot ulcers. Eur J Intern Med 2003;14:341-3.
38. Martinez-Gomez Dde A, Ramirez-Almagro C, Campillo-Soto A, Morales-Cuenca G, Pagán-Ortiz J, Aguayo-Albasini JL. Diabetes foot infections: prevalence and antibiotic sensitivity of the causative organisms. Enferm Infect Microbiol Clin 2009;27:317-21.
39. Richard JL, Sotto A, Jourdan N, Combescure C, Vannereau D, Rodier M, Lavigne JP. Risk factors and healing impact of multidrug resistant bacteria in diabetic foot ulcers. Diabetes Metab 2008;34:363-9.
40. Ramakant P, Verma AK, Misra R, Prasad KN, Chand G, Mishra A, Agarwal G, Agarwal A, Mishra SK. Changing microbiological profile of pathogenic bacteria in diabetic foot infections: time for a rethink on which empirical therapy to choose. Diabetologia 2011;54:58-64.
41. Gadepalli R, Dhawan B, Sreenivas V, Kapil A, Ammini AC, Chaudry R. A clinico-microbiological study of diabetic foot ulcers in an Indian teriary care hospital. Diabetes Care 2006;29:1717-32.
42. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. Characterization of a new metallo-ß-lactames gene, blaNDM-1, and a novel erythromycin estsrease gene carrier on a unique genetic structure in Klebsiella pneumiae sequence typ 14 from India. Antimicrob Agents Chemother 2009;53:5046-54.
43. Rogers BA, Aminzadeh Z, Hayashi Y, Paterson DL. Country-to-country transfer of patients and the risk of multi-resistant bacterial infection. Clin Infect Dis 2011;53:49-56.
44. Richard JL, Sotto A, Jourdan N, Combescure C, Vannereau D, Rodier M, Lavigne JP. Risk factors and healing impact of multidrug-resistant bacteria in diabetic foot ulcers. Diabet Metab 2008;34:363-9.
45. Tentolouris N, Jude EB, Smirnof I, Knowles EA, Boulton AJ. Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med 1999;16:767-71.
46. Vardakas KZ, Horianopoulou M, Falagas ME. Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials. Diabetes Res Clin Pract 2008;80:344-51.
47. Hartemann-Heurtier A, Robert J, Jaqueminet S, Ha Van G, Golmard JN, Jarlier V, Grimaldi A. Diabetic foot ulcer and multidrug resistant organisms: risk factor and impact. Diabet Med 2004;21:710-5.
48. Aragon-Sanchez FJ, Cabrera-Galvan JJ, Quintana-Marero Y, Hernandez-Herrero MJ, Lazaro-Martinez JL, Garcvia-Morales E, Beneit-Montesinos JV, Armstrong DG. Outcome of surgical treatment of diabetic foot osteomyelitis: a series of 185 patients with histopathological confirmation of bone involvement. Diabetologia 2008;51:1962-70.
49. Fejfarova V, Jirkovska A, Skribova J, Petkov V. Pathogen resistance and other risk factors in the frequency of lower limb amputations in patients with the diabetic foot syndrome. Vnitr Lek 2002;48:302-6.
50. Nather A, Bee CS, Huak CY, Chew JL, Lin CB, Neo S, Sim EJ. Epidemiology of diabetic foot problems and predictive factors for limb loss. J Diabetes Complicat 2008;22:77-82.
51. French GL. Bactericidial agents in the treatment of MRSA infections - the potential role of daptomycin. J Antimicrob Chemother 2006;58:1107-17.
52. Stryjewski ME, Chu VH, O'Riordan WD, Warren BL, Dunbar LM, Young DM, Valee M, Fowler VG, Morgenroth J, Barriere SL, Kitt MM, Corey GR. FAST 2 Investigator Group. Telavancin versus standard therapy for treatment of complicated skin and skin-structure infections caused by Gram-positive bacteria: the FAST 2 study. Antimicrob Agents Chemother 2006;50:862-7.
53. Rubino CM, Van Wart SA, Bhavnani SM, Ambrose PG, McCollam JS, Forrest A. Oritavancin pharmacokinetics in healthy subjects and patients with complicated skin and skin-structure infections and bacteremia. Antimicrob Agents Chemother 2009;53:4422-8.
54. Sooto A, Bouziges N, Jourdan N, Richard JL, Lavigne JP. In vitro activity of tigecycline against strains isolated from diabetic foot ulcers. Pathol Biol 2007;55:398-406.
55. Breedt J, Teras J, Gardovskis J, Maritz FJ, Vaasna T, Ross DP, Gioud-Paquet M, Dartois N, Ellis-Grosse EJ, Loh E. Safety and efficacy of tigecycline in the treatment of skin and skin structure infections. Results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005;49:4658-66.
56. Sacchdanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E. Efficacy and safety of tigecycline monotherapy compared to vancomycin plus aztreonam in patients with complicated skin and skin-structure infections: results from a phase 3 randomised double-blind trial. Int J Infect Dis 2005;9:251-61.
57. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E. Tigecycline 200 Study Group. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004;26:704-14.
58. Grosse EJ, Babinchank T, Dartois N, Rose G, Loh E. Tigecycline 300 and 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Inf Dis 2005;41:S341-53.
59. Borbone S, Campanile F, Bongiorno D, Stefani S. In vitro bactericidial activity of ceftobiprole against hospital and community associated methicillin-resistant Staphyloccous aureus. J Antimicrob Chemother 2010;65:591-4.
60. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trail comparing ceftobriprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008;46:647-55.
61. Legat FJ, Maier A, Dittrich P, Zenahlik P, Kern T, Nuhsbaumer S, Frossard M, Salmhofer W, Kerl H, Müller M. Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome. Antimicrob Agents Chemother 2003;47:371-4.
62. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 2005;55:240-5.
63. Tillotson GS, Draghi DC, Sahm DC, Tomfohrde KM, Fabro T, Critchley IA. Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study. J Antimicrob Chemother 2008;62:109-15.
64. Nichols RL, Graham DR, Barriere SL, Rodgers A, Wilson SE, Zervos M, Dunn DL, Kreter B. Treatment of hospitalized patients with complicated Gram-positive skin and skin-structure infections: two randomized, multicentre studies of qionopristin/dafopristin versus cefazolin, oxacillin or vancomycin. J Antimicrob Chemother 1999;44:263-73.
65. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin Infect Dis 2004;38:994-1000.
66. Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DR. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs 2009;18:921-44.
67. Schintler MV, Traunmüller F, Metzler J, Kreuzwirt G, Spendel S, Mauric O, Popovic M, Schranagl E, Joukhadar C. High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimicrob Chemother 2009;64:574-8.
68. Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 2004;53:669-74.
69. Kanafani ZA, Kourany WM, Fowler VG, Levine DP, Vigliani GA, Campion M, Katz DE, Corey GR, Boucher HW. Clinical characteristics and outcomes of diabetic patients with Staphyloccous aureus bacteremia and endocarditis. Eur J Clin Microbiol Infect Dis 2009;28:1477-82.
70. Leighton A, Gottlieb AB, Dorr MB, Jabes D, Mosconi G, VanSaders C, Mroszczak EJ, Campbell KC, Kelly E. Tolerability, pharmacokinetic and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004;48:940-5.
71. Zhanel GG, Decorby M, Adam H, Mulvey MR, McCrackken M, Lagace-Wiens P, Nichol KA, Wierzbowski A, Baudry PJ, Tailor F, Larlowsky JA, Walkty A, Schweizer F, Johnson J. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance study (CANWARD 2008). Antimicrob Agents Chemother 2010;54:4684-93.
72. Yin LY, Lazzarini L, Li F, Stevens CM, Calhoun JH. Comparative evaluation of tigeycline and vancomycin with and without rifampicin in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 2005;55:995-1002.
73. Goldstein EJC, Citron DM, Warren YA, Tyrell KL, Merriam CV, Fernandez HAT. In vitro activities of Dalbavancin and 12 other agents against 329 aerobic and anaerobic Gram-positive isolates recovered from diabetic foot infections. Antimicrob Agents Chemother 2006;50:2875-9.
74. Jauregui LE, Babazadeh S, Seltzer E, Goldberg L, Krievins D, Frederick M, Krause D, Satilovs I, Endzinas Z, Breaux J, O'Riordan W. Randomized, double blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005;15:1407-15.
75. Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR. Telavancin versus vancomycin for the treatment of complicated skin and skin structure infections caused by Gram-positive organisms. Clin Infect Dis 2008;46:1683-93.
76. Fernandez J, Hilliard JJ, Abbanat D, Zhang W, Melton JL, Santoro CM, Flamm RK, Bush K. In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010;54:116-25.
77. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin-structure infections caused by Gram-positive bacteria. Antimicrob Agents Chemother 2008;52:37-44.
78. Sader HS, Fritsche TR, Jones RN. Potency and bactericidal activity of iclaprim against recent clinical Gram-positive isolates. Antimicrob Agents Chemother 2009;53:2171-5.
79. Weems JJ, Steinberg JP, Filler S, Baddley JW, Corey GR, Sampathkumar P, Winston L, John JF, Kubin CJ, Talwani R, More T, Patti JM, Hetherington S, Texter M, Wenzel E, Kelley VA, Fowler VG. Phase II, randomized double-blind multicenter study comparing the safety and phamacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006;50:2751-5.
80. Adam HJ, Louie L, Watt C, Gravel D, Bryce E, Loeb M, Matlkow A, McGeer A, Mulvey MR, Simor AE. Detection and characterization of hetergenous vancomycin-intermediate Staphyloccous aureus isolates in Canada: results from the Canadian nosocomial infection surveillance program 1995-2006. Antimicrob Agents Chemother 54;2010:945-9.
81. Sader HS, Fey FD, Limaye AP, Madinger N, Pankey G, Rahal J, Rybak MJ, Snydman DR, Steed LL, Waites K, Jones RN. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine US Medical centers from 2002-2006. Antimicrob Agents Chemother 2009;53:4127-32.
82. Stein GE, Schooley S, Peloquin CA, Missavage A, Havlichek DH. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother 2007;60:819-23.
83. Lipsky BA, Itani K, Norden C. Linezolid diabetic foot infections study group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin/amoxicillin-clavulanate. Clin Infect Dis 2004;38:17-24.
84. Cenizal MJ, Skiest D, Luber S, Bedimo R, Davies P, Fox P, Delaney K, Hardy RD. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007;51:2628-30.
85. Mendes RE, Sader HS, Deshpande L, Jones RN. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagn Microbiol Infect Dis 2008;60:433-6.
86. Jorgen B, Merckoll P, Melby KK. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin-resistant and methicillin-sensitive S. aureus from the Oslo area. Scand J Infect Dis 2007;39:1059-62.
87. Fluit AC, Schmitzu FJ, Verhoef J, Milatovic D. In vitro activity of daptomycin against Gram-positive European clinica isolates with defined resistant determinants. Antimicrob Agents Chemother 2004;48:1007-11.
88. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI, Daptomycin 98-01 and 99-01 investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673-81.
89. Putnam SD, Sader HS, Farrell DJ, Jones RN. Sustained antimicrobial activity of tigecycline against methicillin-resistant Staphylococcus aureus (MRSA) from United States Medical Centers from 2004 through 2008. J Chemother 2010;22:13-6.
90. Kandemir O, Oztuna V, Colak M, Akdag A, Camdeviren H. Comparison of the efficacy of tigecycline and teicoplanin in an experimental methicillin-resistant Staphylococcus aureus osteomyelitis model. J Chemother 2008;20:53-7.
91. Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infections. Clin Infect Dis 2010;51:641-50.
92. Schneider P, Hawser S, Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett 2003;13:4217-21.
93. Krievins D, Brandt R, Hawser S, Hadvary P, Islam K. Multicenter, randomized study on the efficacy and safety of intravenous iclaprim in complicated skin and skin-structure infections. Antimicrob Agents Chemother 2009;53:2834-40.
94. Domanski PJ, Patel PR, Bayer AS, Zhang L, Hall AE, Syribeys PJ, Gorovis EL, Bryant D, Vernachio JH, Hutchins JT, Patti JM. Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus. Infect Immun 2005;73:5229-32.